We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...
NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, ...
Anhydrous sodium thiosulfate, also known as Pedmarqsi and made by Norgine, is recommended in final draft guidance for preventing hearing loss caused by cisplatin chemotherapy in children from the ages ...
Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a ...
Tirzepatide has been studied in weight management in 2 large, phase 3 studies: SURMOUNT‑1 (n=2,539) in people who did not have diabetes and SURMOUNT‑2 (n=938) in people with type 2 diabetes. Both ...
NICE has produced a resource impact assessment tool for tirzepatide. NICE estimates that the total eligible population is 3.4 million people, and expects that an interim NHS England commissioning ...
NICE's medicines practice guideline on developing and updating local formularies recommends that medicines recommended in NICE technology appraisals are adopted into local formularies automatically ...
NICE inherited the 7 highly specialised technologies (HST) routing criteria from AGNSS (Advisory Group for National Specialised Services) in 2013. Following that, the NICE Highly Specialised ...
Tirzepatide should be thought about as an option for individual people in line with NICE's guideline on overweight and obesity management. The visual summary care pathway has an overview. Table 4 is ...
Tirzepatide (Mounjaro, Eli Lilly) is indicated for 'weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults ...